Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors

Abstract Artificial bone graft substitutes, such as Calcibon, are becoming increasingly interesting as they do not cause donor site morbidity which is an advantage compared to autologous bone grafts. The aim of this study was to evaluate the efficacy and potential complications associated with the u...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joerg Friesenbichler, Werner Maurer-Ertl, Marko Bergovec, Lukas A. Holzer, Kathrin Ogris, Lukas Leitner, Andreas Leithner
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/dced57d5ce424c1daf88dda5487ac74d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dced57d5ce424c1daf88dda5487ac74d
record_format	dspace
spelling	oai:doaj.org-article:dced57d5ce424c1daf88dda5487ac74d2021-12-02T16:08:10ZClinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors10.1038/s41598-017-02048-w2045-2322https://doaj.org/article/dced57d5ce424c1daf88dda5487ac74d2017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02048-whttps://doaj.org/toc/2045-2322Abstract Artificial bone graft substitutes, such as Calcibon, are becoming increasingly interesting as they do not cause donor site morbidity which is an advantage compared to autologous bone grafts. The aim of this study was to evaluate the efficacy and potential complications associated with the use of Calcibon. Twenty-seven patients with benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity. Based on the radiological classification system of Neer, these lesions only comprised Grade I lesions, describing cysts that only require curettage and filling, but no additional treatment. At a mean follow up of six months we observed radiological consolidation without resorption of the bone graft substitute. These observations were also made at a mean follow-up of 13 and 32 months, respectively. According to the classification system of Goslings and Gouma we observed six surgical complications. Summing up, Calcibon seems to be a reliable bone graft substitute with low complication rates. However, delayed resorption should be expected. Calcibon seems to be an alternative to autologous bone grafts or allografts in adequate indications.Joerg FriesenbichlerWerner Maurer-ErtlMarko BergovecLukas A. HolzerKathrin OgrisLukas LeitnerAndreas LeithnerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-5 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Joerg Friesenbichler Werner Maurer-Ertl Marko Bergovec Lukas A. Holzer Kathrin Ogris Lukas Leitner Andreas Leithner Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors
description	Abstract Artificial bone graft substitutes, such as Calcibon, are becoming increasingly interesting as they do not cause donor site morbidity which is an advantage compared to autologous bone grafts. The aim of this study was to evaluate the efficacy and potential complications associated with the use of Calcibon. Twenty-seven patients with benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity. Based on the radiological classification system of Neer, these lesions only comprised Grade I lesions, describing cysts that only require curettage and filling, but no additional treatment. At a mean follow up of six months we observed radiological consolidation without resorption of the bone graft substitute. These observations were also made at a mean follow-up of 13 and 32 months, respectively. According to the classification system of Goslings and Gouma we observed six surgical complications. Summing up, Calcibon seems to be a reliable bone graft substitute with low complication rates. However, delayed resorption should be expected. Calcibon seems to be an alternative to autologous bone grafts or allografts in adequate indications.
format	article
author	Joerg Friesenbichler Werner Maurer-Ertl Marko Bergovec Lukas A. Holzer Kathrin Ogris Lukas Leitner Andreas Leithner
author_facet	Joerg Friesenbichler Werner Maurer-Ertl Marko Bergovec Lukas A. Holzer Kathrin Ogris Lukas Leitner Andreas Leithner
author_sort	Joerg Friesenbichler
title	Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors
title_short	Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors
title_full	Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors
title_fullStr	Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors
title_full_unstemmed	Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors
title_sort	clinical experience with the artificial bone graft substitute calcibon used following curettage of benign and low-grade malignant bone tumors
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/dced57d5ce424c1daf88dda5487ac74d
work_keys_str_mv	AT joergfriesenbichler clinicalexperiencewiththeartificialbonegraftsubstitutecalcibonusedfollowingcurettageofbenignandlowgrademalignantbonetumors AT wernermaurerertl clinicalexperiencewiththeartificialbonegraftsubstitutecalcibonusedfollowingcurettageofbenignandlowgrademalignantbonetumors AT markobergovec clinicalexperiencewiththeartificialbonegraftsubstitutecalcibonusedfollowingcurettageofbenignandlowgrademalignantbonetumors AT lukasaholzer clinicalexperiencewiththeartificialbonegraftsubstitutecalcibonusedfollowingcurettageofbenignandlowgrademalignantbonetumors AT kathrinogris clinicalexperiencewiththeartificialbonegraftsubstitutecalcibonusedfollowingcurettageofbenignandlowgrademalignantbonetumors AT lukasleitner clinicalexperiencewiththeartificialbonegraftsubstitutecalcibonusedfollowingcurettageofbenignandlowgrademalignantbonetumors AT andreasleithner clinicalexperiencewiththeartificialbonegraftsubstitutecalcibonusedfollowingcurettageofbenignandlowgrademalignantbonetumors
_version_	1718384623748120576

Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors

Ejemplares similares